Phase I/IB Trial of Eribulin and Everolimus in Patients With Triple Negative Metastatic Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Sep 2018
Price : $35 *
At a glance
- Drugs Eribulin (Primary) ; Everolimus (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Sep 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 07 Sep 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 08 Mar 2018 Status changed from recruiting to active, no longer recruiting.